A 22-gene classifier flags early metastasis after prostatectomy

Open paper intelligence

In Mayo radical-prostatectomy men, a 22-marker genomic classifier from primary-tumour expression predicted early clinical metastasis after PSA rise better than clinical variables (validation AUC 0.75).

Source

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

Erho N, Crisan A, Vergara IA, et al. · PloS one · 2013

doi.org/10.1371/journal.pone.0066855 Read the full paper ↗552 citationscc by

Study at a glance

Design: Case-control — Nested case-control of Mayo Clinic radical-prostatectomy patients; genomic classifier for early metastasis
N: N=545 · 545 unique expression profiles from a 639-patient nested case-control sample; median follow-up 16.9 years
Population: Men after radical prostatectomy with biochemical recurrence risk for metastasis
Outcome: Genomic classifier discrimination for early clinical metastasis (validation AUC)

Structured fields used in claim comparison tables when every cited study has a complete layer.

What they did

Using a nested case-control sample of 639 Mayo Clinic radical-prostatectomy patients (1987–2001), authors built a random-forest genomic classifier (GC) of 22 expression markers on high-density arrays, focused on early clinical metastasis after biochemical recurrence, and tested performance in a withheld validation set against clinical factors and prior signatures.

What they found

Expression profiles from 545 unique samples (median follow-up 16.9 years) supported GC validation AUC 0.75 (0.67–0.83), outperforming clinical variables and prior gene signatures. GC was the only significant prognostic factor in multivariable analyses; high GC within Gleason groups tracked earlier prostate-cancer death and reduced overall survival.

The limits

What it doesn't show

Improving metastasis prediction is not the same as proving that treating by GC score improves survival in an RCT. The design enriches for PSA-rise/metastasis cases from a surgical registry — not every newly diagnosed man. AUC 0.75 is useful discrimination, not perfect triage.

Key terms

Genomic classifier (GC): 22-marker random-forest expression score (0–1) for early metastasis risk after PSA rise.
Early clinical metastasis: Regional/distant metastases confirmed by imaging within a defined window after biochemical recurrence.
Biochemical recurrence: Rising PSA after prostatectomy — enrichment setting for classifier development.
Nested case-control: Mayo registry design selecting metastasis cases and controls from radical-prostatectomy patients.
Validation AUC: 0.75 (0.67–0.83) discrimination for GC in the withheld validation set.

Flashcards

1 / 10

Research intelligence for this paper

See its role on concept claims, tensions it is part of, placement history, and related discoveries.

Open paper intelligence

Quiz yourself

1 / 6

GC mainly predicts?

Common questions

What does GC predict?

Early clinical metastasis after biochemical recurrence, using primary-tumour expression.

How many markers are in GC?

A random-forest classifier of 22 markers.

What validation AUC was reported?

0.75 (95% interval 0.67–0.83), beating clinical variables and prior signatures.

Who was studied?

Mayo radical-prostatectomy registry patients (639 selected; 545 with usable expression profiles).

Does this prove GC-guided treatment helps?

No — it improves risk discrimination; treatment-by-GC benefit still needs interventional evidence.